<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02776059</url>
  </required_header>
  <id_info>
    <org_study_id>SCAH Consortium- AH Treatment</org_study_id>
    <secondary_id>5U01AA021886</secondary_id>
    <nct_id>NCT02776059</nct_id>
  </id_info>
  <brief_title>Pegfilgrastim in Patients With Alcoholic Hepatitis</brief_title>
  <official_title>A Phase II, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Pegfilgrastim (Neulasta®) in Patients With Alcoholic Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Timothy Morgan, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern California Institute for Research and Education</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, prospective, randomized trial of standard of care vs. standard of
      care + pegfilgrastim (Neulasta®) among patients with a clinical diagnosis of alcoholic
      hepatitis and DF≥32.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard of care treatment will be with either prednisolone 40 mg/day for 28 days or
      pentoxifylline 400 mg TID for 28 days. The patient's physician will decide the standard of
      care treatment the patient will receive. Patients will be randomized (1:1) to receive either
      no additional drug treatment (SOC group) or to receive a pegfilgrastim (Neulasta®, 6 mg) SQ.

      Patients will be seen in-person at screening, randomization (Day 1), Day 8, Day 29, Week 12,
      and Week 24. Safety examination and blood tests will be performed. In addition, biological
      specimens will be saved for research purposes at these time points.

      Total duration of patient participation is 24 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2017</start_date>
  <completion_date type="Anticipated">December 2033</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events, especially infection and renal failure, Change in MELD Score and DF between Day 1 and Day 29, Lille score (at Day 8)</measure>
    <time_frame>Day 1, Day 8, Day 29, and Day 90</time_frame>
    <description>The primary outcome will be survival at Day 90. Assuming a fixed sample size of 70 patients (35 per arm), a one-sided z-test will have 81.6% power to detect a 25% improvement in survival proportions between arms, with survival in the standard of care arm at 65%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>24 weeks</time_frame>
    <description>adverse events through Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function</measure>
    <time_frame>Day 29</time_frame>
    <description>Change in MELD and Maddrey DF during first 4 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver function</measure>
    <time_frame>Day 8</time_frame>
    <description>Change in Lille score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>at Day 90</time_frame>
    <description>survival at Day 90</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>prednisolone or pentoxifylline + pegfiltrastim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>prednisolone or pentoxifylline for 28 days PO plus pegfilgrastim subcutaneous weekly shot</description>
  </arm_group>
  <arm_group>
    <arm_group_label>prednisolone or pentoxifylline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>prednisolone or pentoxifylline for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care + pegfiltrastim</intervention_name>
    <description>prednisolone or pentoxifyline orally for 28 days + pegfilgrastim (Neulasta®) 6 mg in 0.6 mL SQ</description>
    <arm_group_label>prednisolone or pentoxifylline + pegfiltrastim</arm_group_label>
    <other_name>Neulasta®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Oral prednisolone or pentoxifyline for 28 days only</description>
    <arm_group_label>prednisolone or pentoxifylline</arm_group_label>
    <other_name>prednisolone or pentoxifyline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A clinical diagnosis of alcoholic hepatitis with Maddrey's discriminant function score
             ≥32. Age 18 years or older.

        Exclusion Criteria:

          -  Renal failure (creatinine &gt;2.0 mg/dl)

          -  Bilirubin &lt;5 mg/dL

          -  uncontrolled recent upper gastrointestinal bleeding

          -  Known HIV infection

          -  Uncontrolled infection, or pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Morgan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>VA Long Beach Healthcare System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Timothy Morgan, MD</last_name>
    <phone>562 826 5756</phone>
    <email>timothy.morgan@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aliya Asghar, MPH</last_name>
    <phone>562 826 5212</phone>
    <email>aliya.asghar@va.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VA Loma Linda Healthcare System</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92357</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel C Chao, MD</last_name>
      <phone>909-825-7084</phone>
      <phone_ext>6141</phone_ext>
      <email>Daniel.Chao@va.gov</email>
    </contact>
    <investigator>
      <last_name>Daniel C Chao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA Long Beach Healthcare System</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>98022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Morgan, MD</last_name>
      <phone>562-826-5756</phone>
      <email>timothy.morgan@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Aliya Asghar, MPH</last_name>
      <phone>562 826 5212</phone>
      <email>Aliya.asghar@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>LAC-USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Stolz, MD</last_name>
      <phone>323-442-2699</phone>
      <email>astolz@usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Tayek, MD</last_name>
      <phone>310-222-1237</phone>
      <email>jtayek@ladhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Michael W Fleischman, MD</last_name>
      <phone>310 222-2475</phone>
      <email>wfleischman@labiomed.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>New Mexico VA Health Care System</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph M. Alcorn, MD</last_name>
      <phone>505-265-1711</phone>
      <phone_ext>4801</phone_ext>
      <email>Joseph.Alcorn@va.gov</email>
    </contact>
    <investigator>
      <last_name>Joseph M. Alcorn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2016</study_first_submitted>
  <study_first_submitted_qc>May 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2016</study_first_posted>
  <last_update_submitted>November 12, 2017</last_update_submitted>
  <last_update_submitted_qc>November 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Southern California Institute for Research and Education</investigator_affiliation>
    <investigator_full_name>Timothy Morgan, MD</investigator_full_name>
    <investigator_title>Chief of Hepatology</investigator_title>
  </responsible_party>
  <keyword>survival</keyword>
  <keyword>pegfilgrastim</keyword>
  <keyword>cirrhosis, alcoholic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patients' coded data will be shared .</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

